May 16, 2018 / 9:16 PM / 7 months ago

BRIEF-Genentech Says In Phase 3 Impower150 Study, Survival Advantage For Tecentriq-Avastin Combo Was Seen In All Exploratory Patient Subgroups Analyzed

May 16 (Reuters) - GENENTECH:

* PHASE III IMPOWER150 STUDY SHOWED GENENTECH’S TECENTRIQ AND AVASTIN PLUS CARBOPLATIN AND PACLITAXEL HELPED PEOPLE WITH A SPECIFIC TYPE OF METASTATIC LUNG CANCER LIVE SIGNIFICANTLY LONGER COMPARED TO AVASTIN PLUS CARBOPLATIN AND PACLITAXEL

* GENENTECH - IN PHASE III IMPOWER150 STUDY, SURVIVAL ADVANTAGE FOR TECENTRIQ-AVASTIN COMBO REGIMEN WAS SEEN IN ALL EXPLORATORY PATIENT SUBGROUPS ANALYZED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below